• Group revenues from sales of goods and royalties amounted to 1,016 (936) MSEK.

• Earnings per share amounted to 6.38 (0.78) SEK.

• Operating income amounted to 676 (100) MSEK.

• In April 2009 Q-Med AB and Oceana Therapeutics, LCC., based in the US, entered into global agreements regarding commercialization rights to Deflux® and Solesta™. The agreements gave Q-Med an initial payment of 517 MSEK in total in June, partly as a purchase sum for Q-Med Scandinavia, Inc., the subsidiary that was divested within the framework of the agreements, and partly as payment for Oceana’s share of certain study costs. The net revenue of 496 MSEK has been recorded in the Group income statement in the Other operating revenues row.

• Revenues within the Esthetics product area amounted to 846 (765) MSEK and operating income was 195 (177) MSEK. For the Hospital Healthcare product area revenues from sales of goods and royalties were 170 (171) MSEK and operating income was 537 (-22) MSEK. Operating...